These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24738551)

  • 21. Cabotegravir long-acting for HIV-1 prevention.
    Andrews CD; Heneine W
    Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.
    Rathbun RC; Lockhart SM; Miller MM; Liedtke MD
    Ann Pharmacother; 2014 Mar; 48(3):395-403. PubMed ID: 24259658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Advances in Antiretroviral Agents: Potent Integrase Inhibitors.
    Psichogiou M; Poulakou G; Basoulis D; Paraskevis D; Markogiannakis A; Daikos GL
    Curr Pharm Des; 2017; 23(18):2552-2567. PubMed ID: 28356041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor.
    Spreen W; Min S; Ford SL; Chen S; Lou Y; Bomar M; St Clair M; Piscitelli S; Fujiwara T
    HIV Clin Trials; 2013; 14(5):192-203. PubMed ID: 24144896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors.
    Yoshinaga T; Seki T; Miki S; Miyamoto T; Suyama-Kagitani A; Kawauchi-Miki S; Kobayashi M; Sato A; Stewart E; Underwood M; Fujiwara T
    Antiviral Res; 2018 Apr; 152():1-9. PubMed ID: 29410019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis.
    Veselinovic M; Yang KH; Sykes C; Remling-Mulder L; Kashuba AD; Akkina R
    Virology; 2016 Feb; 489():173-8. PubMed ID: 26771889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.
    McGowan I; Dezzutti CS; Siegel A; Engstrom J; Nikiforov A; Duffill K; Shetler C; Richardson-Harman N; Abebe K; Back D; Else L; Egan D; Khoo S; Egan JE; Stall R; Williams PE; Rehman KK; Adler A; Brand RM; Chen B; Achilles S; Cranston RD
    Lancet HIV; 2016 Dec; 3(12):e569-e578. PubMed ID: 27658864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir.
    Han Y; Luo H; Lu Q; Liu Z; Liu J; Zhang J; Wei Z; Li J
    Molecules; 2021 Nov; 26(23):. PubMed ID: 34885762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
    van Lunzen J; Maggiolo F; Arribas JR; Rakhmanova A; Yeni P; Young B; Rockstroh JK; Almond S; Song I; Brothers C; Min S
    Lancet Infect Dis; 2012 Feb; 12(2):111-8. PubMed ID: 22018760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An overview of antiretroviral pre-exposure prophylaxis of HIV infection.
    McGowan I
    Am J Reprod Immunol; 2014 Jun; 71(6):624-30. PubMed ID: 24635047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
    PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.
    Lykins WR; Luecke E; Johengen D; van der Straten A; Desai TA
    Drug Deliv Transl Res; 2017 Dec; 7(6):805-816. PubMed ID: 28612340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Modern HIV treatment].
    Lehmann C; Malin J; Suárez I; Fätkenheuer G
    Internist (Berl); 2019 Apr; 60(4):411-419. PubMed ID: 30778612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The promise and pitfalls of long-acting injectable agents for HIV prevention.
    Landovitz RJ; Kofron R; McCauley M
    Curr Opin HIV AIDS; 2016 Jan; 11(1):122-8. PubMed ID: 26633643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virology. A bid to thwart HIV with shot of long-lasting drug.
    Cohen J
    Science; 2014 Mar; 343(6175):1067. PubMed ID: 24604173
    [No Abstract]   [Full Text] [Related]  

  • 36. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.
    Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P;
    Lancet; 2016 Feb; 387(10018):566-573. PubMed ID: 26603917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of dolutegravir in treatment-experienced patients: the SAILING and VIKING trials].
    Moreno S; Berenguer J
    Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():26-30. PubMed ID: 25858609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Qualitative Consumer Research on Acceptance of Long-Acting Pre-Exposure Prophylaxis Products Among Men Having Sex with Men and Medical Practitioners in the United States.
    Calder BJ; Schieffer RJ; Bryndza Tfaily E; D'Aquila R; Greene GJ; Carballo-Diéguez A; Giguere R; Kiser PF; Hope TJ
    AIDS Res Hum Retroviruses; 2018 Oct; 34(10):849-856. PubMed ID: 30229684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM; Schafer JJ; Desimone JA
    Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.